The use of the R6 transgenic mouse models of Huntington' s disease in attempts to develop novel therapeutic strategies

被引：163
作者：
Li J.Y. [1 ]
Popovic N. [1 ]
Brundin P. [1 ]
机构：
[1] Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science
来源：
NeuroRX | 2005年 / 2卷 / 3期
关键词：
Huntington's disease; Neurodegenerative diseases; R6/2; Therapy; Transgenic mice;
D O I：
10.1602/neurorx.2.3.447
中图分类号：
学科分类号：
摘要：
Huntington's disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future. © The American Society for Experimental NeuroTherapeutics, Inc.
引用
收藏
页码：447 / 464
页数：17
相关论文
共 155 条
[41]  
Petersen A., Larsen K.E., Behr G.G., Romero N., Przedborski S., Brundin P., Et al., Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration, Hum Mol Genet, 10, pp. 1243-1254, (2001)
[42]  
Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Et al., Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease, J Neurosci Res, 58, pp. 515-532, (1999)
[43]  
Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Et al., Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease, J Neurosci, 23, pp. 961-969, (2003)
[44]  
Nicniocaill B., Haraldsson B., Hansson O., O'Connor W.T., Brundin P., Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice, Eur J Neurosci, 13, pp. 206-210, (2001)
[45]  
Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Et al., Impaired glutamate uptake in the R6 Huntington's disease transgenic mice, Neurobiol Dis, 8, pp. 807-821, (2001)
[46]  
Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B., Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the Huntington mutation, Brain, 125, pp. 1908-1922, (2002)
[47]  
Hickey M.A., Reynolds G.P., Morton A.J., The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease, J Neurochem, 81, pp. 46-59, (2002)
[48]  
Reynolds G.P., Dalton C.F., Tillery C.L., Mangiarini L., Davies S.W., Bates G.P., Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation, J Neurochem, 72, pp. 1773-1776, (1999)
[49]  
Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Et al., Striatal neurochemical changes in transgenic models of Huntington's disease, J Neurosci Res, 68, pp. 716-729, (2002)
[50]  
Yohrling I.G., Jiang G.C., DeJohn M.M., Robertson D.J., Vrana K.E., Cha J.H., Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease, J Neurochem, 82, pp. 1416-1423, (2002)
12345678910